Refractory folliculitis decalvans treated with adalimumab: A case series of 23 patients - 19/08/22
, Michela Starace, MD, PhD b, Sergio Vano-Galvan, MD, PhD c, Bianca Maria Piraccini, MD, PhD b, Pascal Reygagne, MD, PhD d, Lidia Rudnicka, MD, PhD e, Tatiana Silyuk, MD f, Rodney Sinclair, MD, PhD g, Antonella Tosti, MD hKey words : adalimumab, biologics, cicatricial alopecia, folliculitis decalvans, hair disorders, hair loss, scarring alopecia, treatment
| Funding sources: None. |
|
| IRB approval status: Approved by the institutional review board of the University Hospital Ramón y Cajal (ACTA 418 - 7/9/21), Madrid, Spain. |
Vol 87 - N° 3
P. 666-669 - settembre 2022 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
